Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy. However, because ICIs block coinhibitory molecules on T cells and other immune cells, unleashing them to mediate tumor cell killing, they also can disrupt the maintenance of immunological tolerance to self‐antigens. Compared with chemotherapy, ICIs have a different toxicity profile, especially the occurrence of autoimmune‐like manifestations against multiple organ systems, including endocrine glands, commonly referred to as immune‐related adverse events. The aim of this review was to provide practical recommendations regarding the proper assessment and clinical management related to the new onset of endocrinopathies after the use of ICIs in patients with cancer. Cancer 2018;124:1111‐21. © 2018 American Cancer Society.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Freeman, G. J., Long, A. J., Iwai, Y., Bourque, K., Chernova, T., Nishimura, H., Fitz, L. J., Malenkovich, N., Okazaki, T., Byrne, M. C., et al. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.7.1027 · Cited by 5,294 · cited 1×
“Immune checkpoint molecules are crucial for maintaining immunological tolerance to self-antigens.(5,6) Not surprisingly, ICIs have a particular toxicity profile, characterized by autoimmune-like manifestations against multiple organ systems,(7) including the gastrointestinal tract, skin, and endocrine glands,(8) commo…”
BackgroundImmune Checkpoint Blockade: A Common Denominator Approach to Cancer Therapy
Topalian, S. L., Drake, C. G., & Pardoll, D. M. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.03.001 · Cited by 4,229
Enhancement of Antitumor Immunity by CTLA-4 Blockade
Leach, D. R., Krummel, M. F., & Allison, J. P. (1996) · Science · doi:10.1126/science.271.5256.1734 · Cited by 3,955
Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease
Ueda, H., Howson, J. M. M., Esposito, L., Heward, J., Snook, Chamberlain, G., Rainbow, D. B., Hunter, K. M. D., Smith, A. N., Di Genova, G., et al. (2003) · Nature · doi:10.1038/nature01621 · Cited by 2,175
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127 · cited 1×
“After the use of ICIs, endocrine irAEs frequently have been reported in clinical trials, including cases of hypothyroidism, hyperthyroidism, hypophysitis, primary adrenal insufficiency (AI), and autoimmune diabetes mellitus (DM).(7) With the increased use of ICIs in clinical practice, endocrine irAEs mediated by ICI a…”
Jonklaas, J., Bianco, A. C., Bauer, A. J., Burman, K. D., Cappola, A. R., Celi, F. S., Cooper, D. S., Kim, B. W., Peeters, R. P., Rosenthal, M. S., et al. (2014) · Thyroid® · doi:10.1089/thy.2014.0028 · Cited by 1,928
Bornstein, S. R., Allolio, B., Arlt, W., Barthel, A., Don-Wauchope, A., Hammer, G. D., Husebye, E. S., Merke, D. P., Murad, M. H., Stratakis, C. A., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1710 · Cited by 1,769 · cited 1×
“Patients with either primary or central hypocortisolism must receive hormone replacement according to the current guidelines.(51) The management of AI, including adrenal crisis, is presented in Table 1.”
MethodPhan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575 · cited 1×
“Immune checkpoint molecules are crucial for maintaining immunological tolerance to self-antigens.(5,6) Not surprisingly, ICIs have a particular toxicity profile, characterized by autoimmune-like manifestations against multiple organ systems,(7) including the gastrointestinal tract, skin, and endocrine glands,(8) commo…”
BackgroundManagement of Immune-Related Adverse Events and Kinetics of Response With Ipilimumab
Weber, J. S., Kähler, K. C., & Hauschild, A. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2012.41.6750 · Cited by 1,415
Barroso-Sousa, R., Barry, W. T., Garrido-Castro, A. C., Hodi, F. S., Min, L., Krop, I. E., & Tolaney, S. M. (2018) · JAMA Oncology · doi:10.1001/jamaoncol.2017.3064 · Cited by 1,115
Hormonal Replacement in Hypopituitarism in Adults: An Endocrine Society Clinical Practice Guideline
Fleseriu, M., Hashim, I. A., Karavitaki, N., Melmed, S., Murad, M. H., Salvatori, R., & Samuels, M. H. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2118 · Cited by 945 · cited 1×
“In general, for asymptomatic patients, we recommend referral to an endocrinologist for the initiation of hormone replacement therapy as needed according to the current guidelines.(47) Management of symptomatic patients may differ depending on the type of clinical presentation.”
MethodLife-Threatening Thyrotoxicosis: Thyroid Storm
Burch, H. B., & Wartofsky, L. (1993) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/s0889-8529(18)30165-8 · Cited by 852
Iwama, S., De Remigis, A., Callahan, M. K., Slovin, S. F., Wolchok, J. D., & Caturegli, P. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008002 · Cited by 715 · cited 1×
“that repeated injections of anti-CTLA-4 MoAbs induced hypophysitis in a mouse model through complementmediated cytotoxicity.(34) In addition, CTLA-4 protein was expressed in both murine and human pituitary glands, and demonstrated the presence of antithyrotroph, anticorticotroph, and antigonadotroph antibodies in the…”
BackgroundOsorio, J. C., Ni, A., Chaft, J. E., Pollina, R., Kasler, M. K., Stephens, D., Rodriguez, C., Cambridge, L., Rizvi, H., Wolchok, J. D., et al. (2017) · Annals of Oncology · doi:10.1093/annonc/mdw640 · Cited by 659
Charmandari, E., Nicolaides, N. C., & Chrousos, G. P. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61684-0 · Cited by 644
Genetic risk factors for type 1 diabetes
Pociot, F., & Lernmark, Å. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30582-7 · Cited by 553
Ryder, M., Callahan, M., Postow, M. A., Wolchok, J., & Fagin, J. A. (2014) · Endocrine-Related Cancer · doi:10.1530/erc-13-0499 · Cited by 439
Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
Faje, A. (2016) · Pituitary · doi:10.1007/s11102-015-0671-4 · Cited by 326 · cited 1×
“Based on data from large and well-described longitudinal cohorts of patients with ipilimumab-induced hypophysitis, central hypothyroidism is the most common endocrine disturbance (93%), followed by hypogonadotropic hypogonadism (86%) and central AI (75%).(36-38,45) Prolactin levels and the growth hormone axis are not…”
MethodDelivanis, D. A., Gustafson, M. P., Bornschlegl, S., Merten, M. M., Kottschade, L., Withers, S., Dietz, A. B., & Ryder, M. (2017) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2017-00448 · Cited by 278
Prevalence of detectable C-peptide according to age at diagnosis and duration of type 1 diabetes
Davis, A. K., DuBose, S. N., Haller, M. J., Miller, K. M., DiMeglio, L. A., Bethin, K. E., Goland, R. S., Greenberg, E. M., Liljenquist, D. R., Ahmann, A. J., et al. (2015) · Diabetes Care · doi:10.2337/dc14-1952 · Cited by 261
Incidence of Thyroid-Related Adverse Events in Melanoma Patients Treated With Pembrolizumab
de Filette, J., Jansen, Y., Schreuer, M., Everaert, H., Velkeniers, B., Neyns, B., & Bravenboer, B. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-2300 · Cited by 244
Morganstein, D. L., Lai, Z., Spain, L., Diem, S., Levine, D., Mace, C., Gore, M., & Larkin, J. (2017) · Clinical Endocrinology · doi:10.1111/cen.13297 · Cited by 190
Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy
Min, L., Vaidya, A., & Becker, C. (2011) · European Journal of Endocrinology · doi:10.1530/eje-10-0833 · Cited by 179
Self-citationClinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study
Yamauchi, I., Sakane, Y., Fukuda, Y., Fujii, T., Taura, D., Hirata, M., Hirota, K., Ueda, Y., Kanai, Y., Yamashita, Y., et al. (2017) · Thyroid · doi:10.1089/thy.2016.0562 · Cited by 169
Characterization of Thyroid Disorders in Patients Receiving Immune Checkpoint Inhibition Therapy
Lee, H., Hodi, F. S., Giobbie-Hurder, A., Ott, P. A., Buchbinder, E. I., Haq, R., Tolaney, S., Barroso-Sousa, R., Zhang, K., Donahue, H., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-17-0208 · Cited by 161 · cited 1×
“In our practice, the majority of symptomatic patients referred to the endocrinology clinic presented with thyrotoxicosis as the first manifestation of their thyroid disorder.(22) Weight changes and tachycardia were the most commonly reported symptoms at presentation, and the median time to the onset of thyrotoxicosis…”
BackgroundSelf-citationOrlov, S., Salari, F., Kashat, L., & Walfish, P. G. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-4560 · Cited by 134
Treatment of Ipilimumab Induced Graves’ Disease in a Patient with Metastatic Melanoma
Azmat, U., Liebner, D., Joehlin-Price, A., Agrawal, A., & Nabhan, F. (2016) · Case Reports in Endocrinology · doi:10.1155/2016/2087525 · Cited by 59
Cited by
Collateral damage: Insulin-dependent diabetes induced with checkpoint inhibitors
Stamatouli, A. M., Quandt, Z., Perdigoto, A. L., Clark, P. L., Kluger, H., Weiss, S. A., Gettinger, S., Sznol, M., Young, A., Rushakoff, R., et al. (2018) · Diabetes · doi:10.2337/dbi18-0002 · Cited by 590
“Thyroiditis, hypophysitis with secondary adrenal insufficiency, secondary hypothyroidism and gonadal deficiency, primary adrenal insufficiency, and insulin-dependent diabetes have been reported following anti–CTLA-4, anti–PD-1, and/or anti–PD-L1 mAbs (16,17).”
Choi, J., & Lee, S. Y. (2020) · Immune Network · doi:10.4110/in.2020.20.e9 · Cited by 298
An update on the pathogenesis of Hashimoto’s thyroiditis.
Weetman, A. P. (2021) · Journal of Endocrinological Investigation · doi:10.1007/s40618-020-01477-1 · Cited by 258
Tan, M. H., Iyengar, R., Mizokami-Stout, K., Yentz, S., MacEachern, M. P., Shen, L. Y., Redman, B., & Gianchandani, R. (2019) · Clinical Diabetes and Endocrinology · doi:10.1186/s40842-018-0073-4 · Cited by 172
Graves’ Disease during Immune Checkpoint Inhibitor Therapy (A Case Series and Literature Review)
Peiffert, M., Cugnet-Anceau, C., Dalle, S., Chikh, K., Assaad, S., Disse, E., Raverot, G., Borson-Chazot, F., & Abeillon-du Payrat, J. (2021) · Cancers · doi:10.3390/cancers13081944 · Cited by 33
Metadata
- Authors
- Barroso‐Sousa, R., Ott, P. A., Hodi, F. S., Kaiser, U. B., Tolaney, S. M., & Min, L.
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2018-01-03
- Volume
- 124
- Issue
- 6
- Pages
- 1111-1121
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W2782261845
- Cited by
- 113
- References
- 27
- FWCI
- 4.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.